

Sirtex Medical Limited (ASX:SRX)

Investor Presentation

Gilman Wong CEO Darren Smith CFO Dr David N. Cade CMO 8th April 2016

Company Overview


- Australian headquartered, global healthcare business
- ✓ Listed on the ASX since 2000 (ASX:SRX)
- S&P / ASX 100 Index inclusion since December 2015
- Z Established track record of earnings growth and building shareholder value
- Single commercialised medical device: SIR-Spheres[®] Y-90 resin microspheres; a liver-directed therapy for the treatment of inoperable liver cancer
- To date, approximately 61,000 doses supplied at more than 950 medical centres in over 40 countries
- Attractive, long term growth potential
- Investment in innovation through collaboration consistent with the 2020 Vision strategy






Financial Overview – FY15

- Record dose sales of 10,252 doses, up 19.8%
- Record revenues of \$176.1 million, up 36.1%
- Record net profit after tax of \$40.3 million, up 69.0%
- Five year CAGR dose sales of 19.7%, revenues 22.3%
- EPS of 71.4 cents up 67.8%, DPS of 20.0 cents, up 42.9%




Financial Overview – 1H16

- Record dose sales of 5,728 doses, up 15.7%
- \sim Record revenues of \$112.6 million, up 40.0%
- Record net profit after tax of \$25.9 million, up 46.9%
- 1H five year CAGR dose sales of 19.8%, revenues 27.0%
- Cash on hand of \$73.7 million, up 33.0% no debt





The cancer treatment paradigm




Treating cancer in the liver is challenging





Surgery

- ightarrow Possible in minority of cases





Liver Transplant Replaces diseased liver
Curative intent
Lifelong immunosuppression



Selective Internal Radiation Therapy


- Proven tumour shrinkage capability

Ablation

- Heat (radiofrequency or microwave)
- Cold (cryotherapy) or chemical (ethanol)
- Palliative intent, percutaneously 'through the skin'



SIR-Spheres exploit the tumour's own blood supply



- Technique known as <u>Selective Internal Radiation Therapy</u> (SIRT) or Radioembolisation
- **7** Delivers high dose radiation therapy to liver tumours "from the inside out"
 - Suitable for primary and secondary (metastatic) forms of liver cancer
- Today, SIRT represents a key component within a whole new area of cancer medicine called Interventional Oncology
- ✓ Sirtex is a global leader




What are SIR-Spheres and what do they do?




SIR-Spheres Y-90 resin microspheres are tiny radioactive resin beads that emit radiation. They are only about one third the width of a human hair and have about the same specific gravity as a red blood cell. This enables the microspheres to flow easily in the blood and become lodged in the small blood vessels around the liver tumour where they destroy it while sparing the surrounding healthy tissue.

Example: colorectal cancer that has spread to the liver




Addressable market – colorectal cancer




- (1) Sirtex markets = APAC: Australia, China, Hong Kong, India, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand. EMEA: Austria, Belgium, Egypt, Estonia, Finland, France, Germany, Greece, Israel, Italy, Poland, Portugal, South Africa, Spain, Sweden, Switzerland, The Netherlands, Turkey, United Kingdom. Americas: Argentina, Brazil, Canada, Mexico, USA
- (2) Hind D, Tappenden P, Tumur I et. al. Technology assessment report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence. 10 January 2005. (3) Sirtex data and analysis.


Elevation to higher treatment lines, including 1st – line, will materially expand the market opportunity

Example: Colorectal Cancer





Addressable market – hepatocellular carcinoma




(1) Sirtex markets = APAC: Australia, China, Hong Kong, India, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand. EMEA: Austria, Belgium, Egypt, Estonia, Finland, France, Germany, Greece, Israel, Italy, Poland, Portugal, South Africa, Spain, Sweden, Switzerland, The Netherlands, Turkey, United Kingdom. Americas: Argentina, Brazil, Canada, Mexico, USA.

(2) Llovet et. al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008.

(3) Sirtex data and analysis.


10

Key tenets for broad commercial adoption





The link between clinical investment and market return



	- XFI Global	RE 🥳	K SARI	AH soramic	
STUDY NAME	START	TOTAL PATIENTS	% RECRUITMENT AT 30 JUNE 2015	% RECRUITMENT AT 31 DEC 2015	TYPE OF LIVER CANCER
SIRFLOX	2006	530	100%	100%	mCRC
FOXFIRE FOXFIRE GLOBAL	2010	573	100%	100%	mCRC
SARAH	2012	460	100%	100%	HCC
SORAMIC	2010	375	85%	97%	НСС
SIRveNIB	2011	360	85%	95%	НСС

Solo

A SORAMIC completed recruitment in March, 2016, SIRveNIB to complete recruitment during current half

Patients with HCC eligible for SIR-Spheres	209,000
Patients with mCRC eligible for SIR-Spheres	279,000

Significantly expanded market opportunity on positive clinical results





Long term market growth potential

- Solid long term growth rates: 5 year CAGR 19.7%, 10 year CAGR 30.1% achieved
- Market expansion strategies will continue to grow the SIR-Spheres business:
 - Deliver new clinical evidence in mCRC/HCC to drive adoption at earlier stages of disease
 - Increase the number of treatment sites, trained clinicians, and throughput
 - Z Expand reimbursement coverage
 - Continued geographic expansion
 - \square Expand into new indications e.g. kidney
 - ~2% penetration of addressable markets implied by FY15 dose sales
 - Each of our regions (The Americas, EMEA, APAC) has equivalent potential

FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15



2020Vision





Our 2020Vision is supported by three pillars

Sirtex's three growth pillars

1 SIR-Spheres microspheres

- Maximise value of SIR-Spheres microspheres for:
 - Primary and secondary liver cancer

2 Research & Development

- Enhance and optimise SIR-Spheres microspheres: 'Evolution'
- New platform technologies with multiple applications
- Allocation of resources commensurate with commercial potential, development milestones and alignment with overall group strategy

3 Mergers & Acquisitions

- Commercial ready technology that will add value and grow the business
- Seeking to capitalise on our capabilities and infrastructure



Summary

- Proven track record of performance over the long term
- SIR-Spheres microspheres business represents a long term growth opportunity
- Estimated addressable patient population of 488,000 per annum in Sirtex's markets, with minimal penetration to date (~2%)
- Continued investment into product and market development essential to build awareness among clinicians and drive sales
- Generation of Level 1 evidence from the current clinical program is an important component progressive delivery of results over next 2+ years
- Continue to progress R&D pipeline towards clinical studies



Thank you

